Guazzelli Cristina Aparecida Falbo, Jacobucci Maria Silvia Bortolotti de Mello, Barbieri Márcia, Araújo Fabio Fernando, Moron Antonio Fernades
Department of Obstetrics and Gynecology of São Paulo Federal University (UNIFESP), Family Planning Clinic, CEP 09090-050 São Paulo, Brasil.
Contraception. 2007 Jul;76(1):45-8. doi: 10.1016/j.contraception.2007.03.007. Epub 2007 May 24.
This prospective noncomparative observational study evaluated the clinical symptoms, body weight and blood pressure of 38 adolescents receiving a monthly injectable contraceptive containing estradiol valerate 5 mg and norethisterone 50 mg.
The volunteers, aged 16-19 years, were examined monthly during 1 year and asked about the following symptoms at baseline: dysmenorrhea, headache, breast tenderness, leg pain and irritability.
There was a constant and gradual decline in each of the above symptoms over time, and there was a statistically significant difference between symptoms reported at the first visit and subsequent appointments. Body weight and blood pressure did not change significantly during the 1-year period. No pregnancies were observed.
These findings suggest that monthly injectable contraception with estradiol valerate 5 mg/norethisterone 50 mg represents a highly effective and well-tolerated contraceptive for teens.